Drug Substance and Drug Product Manufacturing Strategy Assessment for siRNAs
Amgen currently has its first siRNA program, Asset #1 in phase 2 clinical trials. Until recently, Amgen has been outsourcing the Drug Substance (DS) and Drug Product (DP) manufacturing to external manufacturers, but with a growing siRNA portfolio even beyond Asset #1, the building of a new facility...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Published: |
Massachusetts Institute of Technology
2022
|
| Online Access: | https://hdl.handle.net/1721.1/139182 |